Tumor and Systemic Immunomodulatory Effects of MEK Inhibition

Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

(2020) Ralf Gutzmer et al.   LANCET

Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial

(2019) Cathy Eng et al.   LANCET ONCOLOGY

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

(2019) Scott Kopetz et al.   NEW ENGLAND JOURNAL OF MEDICINE

LBA69Combination treatment with cobimetinib (C) and atezolizumab (A) vs pembrolizumab (P) in previously untreated patients (pts) with BRAFV600 wild type (wt) advanced melanoma: Primary analysis from the phase III IMspire170 trial

(2019) A M Arance et al.   ANNALS OF ONCOLOGY

MEK inhibition suppresses B regulatory cells and augments anti-tumor immunity

(2019) Mark Yarchoan et al.   PLoS One

Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy

(2018) Feifei Liu et al.   Acta Pharmaceutica Sinica B

Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA

(2017) Matthew A. Coelho et al.   IMMUNITY

Prognostic significance of PD-L1 in solid tumor

(2017) Qianqian Wang et al.   MEDICINE

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2017) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer

(2017) Sathana Dushyanthen et al.   Nature Communications

The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment

(2017) Edmund Poon et al.   Journal for ImmunoTherapy of Cancer

Selective Sparing of Human Tregs by Pharmacologic Inhibitors of the Phosphatidylinositol 3-Kinase and MEK Pathways

(2016) N. A. Zwang et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Trametinib Drives T-cell–Dependent Control of KRAS-Mutated Tumors by Inhibiting Pathological Myelopoiesis

(2016) Michael J. Allegrezza et al.   CANCER RESEARCH

IL15 Agonists Overcome the Immunosuppressive Effects of MEK Inhibitors

(2016) M. J. Allegrezza et al.   CANCER RESEARCH

MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade

(2016) Peter J.R. Ebert et al.   IMMUNITY

RAS isoforms and mutations in cancer at a glance

(2016) G. Aaron Hobbs et al.   JOURNAL OF CELL SCIENCE

Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells

(2016) E. J. Brea et al.   Cancer Immunology Research

RAS–Mitogen-Activated Protein Kinase Signal Is Required for Enhanced PD-L1 Expression in Human Lung Cancers

(2016) Hidetoshi Sumimoto et al.   PLoS One

The significance of the co-existence of osteopontin and tumor-associated macrophages in gastric cancer progression

(2015) Chang-Ni Lin et al.   BMC CANCER

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

(2015) Suzanne L. Topalian et al.   CANCER CELL

The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4

(2015) L. Liu et al.   CLINICAL CANCER RESEARCH

RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors

(2015) S. Loi et al.   CLINICAL CANCER RESEARCH

Regulatory B Cells: Origin, Phenotype, and Function

(2015) Elizabeth C. Rosser et al.   IMMUNITY

Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages

(2015) Stefano Ugel et al.   JOURNAL OF CLINICAL INVESTIGATION

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

The future of immune checkpoint therapy

(2015) P. Sharma et al.   SCIENCE

Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanoma

(2015) Siwen Hu-Lieskovan et al.   Science Translational Medicine

Tumor-Derived Osteopontin Suppresses Antitumor Immunity by Promoting Extramedullary Myelopoiesis

(2014) E.-K. Kim et al.   CANCER RESEARCH

MHC Class I Loss Is a Frequent Mechanism of Immune Escape in Papillary Thyroid Cancer That Is Reversed by Interferon and Selumetinib Treatment In Vitro

(2014) T. E. Angell et al.   CLINICAL CANCER RESEARCH

Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma

(2014) M. Atefi et al.   CLINICAL CANCER RESEARCH

Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

(2014) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Checkpoint blocking antibodies in cancer immunotherapy

(2013) Chrisann Kyi et al.   FEBS LETTERS

The MAPK Pathway Is a Predominant Regulator of HLA-A Expression in Esophageal and Gastric Cancer

(2013) K. Mimura et al.   JOURNAL OF IMMUNOLOGY

MEK inhibition, alone or in combination with BRAF inhibition, impairs multiple functions of isolated normal human lymphocytes and dendritic cells

(2013) Laura J Vella et al.   Journal for ImmunoTherapy of Cancer

Overexpression and immunosuppressive functions of transforming growth factor 1, vascular endothelial growth factor and interleukin-10 in epithelial ovarian cancer

(2012) Chan-zhen Liu et al.   Chinese Journal of Cancer Research

The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition

(2012) X. Jiang et al.   CLINICAL CANCER RESEARCH

Crosstalk and Signaling Switches in Mitogen-Activated Protein Kinase Cascades

(2012) Dirk Fey et al.   Frontiers in Physiology

OX40 Complexes with Phosphoinositide 3-Kinase and Protein Kinase B (PKB) To Augment TCR-Dependent PKB Signaling

(2011) T. So et al.   JOURNAL OF IMMUNOLOGY

Activation and Function of the MAPKs and Their Substrates, the MAPK-Activated Protein Kinases

(2011) M. Cargnello et al.   MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS

Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function

(2010) A. Boni et al.   CANCER RESEARCH

Small-Molecule Inhibitors of the ERK Signaling Pathway: Towards Novel Anticancer Therapeutics

(2010) Jeremy L. Yap et al.   ChemMedChem

Regulation of Tumor Immunity by Tumor/Dendritic Cell Fusions

(2010) Shigeo Koido et al.   Clinical & Developmental Immunology

T Cell Activation

(2009) Jennifer E. Smith-Garvin et al.   Annual Review of Immunology

B lymphocytes: how they develop and function

(2008) T. W. LeBien et al.   BLOOD

Survival of ovarian cancer patients overexpressing the tumour antigen p53 is diminished in case of MHC class I down-regulation

(2008) Ninke Leffers et al.   GYNECOLOGIC ONCOLOGY

A Regulatory B Cell Subset with a Unique CD1dhiCD5+ Phenotype Controls T Cell-Dependent Inflammatory Responses

(2008) Koichi Yanaba et al.   IMMUNITY